Drug Discovery & Development Products & Reviews

Plasmax™ is a physiologically relevant cell culture medium which closely mimics the nutritional & metabolic profile of human plasma, containing over 80 optimised components.

Syngeneic urothelial carcinoma model for bladder cancer research and immunotherapy development

Highly metastatic murine alveolar lung carcinoma cell line, derived from the CMT 64 line, that is widely used to investigate metastasis, immune responses, and immunoresistance.

KCGS is a comprehensive collection of 295 highly selective kinase inhibitors targeting 262 human kinases

Syngeneic pancreatic ductal adenocarcinoma (PDA) cell line from the KPC mouse model for immune-competent studies in drug discovery, biomarker development, genetic research, and metastasis

Our Metabolite Identification service for peptides utilizes HRMS to characterize peptide metabolism (e.g., hydrolysis, oxidation, glucuronidation). The assay identifies and semi-quantifies metabolites in plasma/tissues, enabling ADME profiling (clearance, bioavailability), toxicity screening (reactive metabolites) and peptide optimization (PK/PD enhancement). Integrated with preclinical data, it supports metabolically stable p…

Our Comprehensive In Vitro Proarrhythmia Assay (CiPA) service assesses proarrhythmic potential of compounds beyond hERG inhibition, integrating effects on multiple cardiac ion channels and human iPSC-derived cardiomyocytes via patch clamp and multi-well MEA platforms. Aligned with FDA's CiPA initiative and ICH E14/S7B guidelines, it predicts QT prolongation and TdP risks for enhanced specificity in early drug safety evaluation…

Our Protein Binding Platform assesses drug-protein interactions using equilibrium dialysis and ultracentrifugation methods to determine unbound fractions and distribution in biological samples including plasma, blood, tissues, and cells. This essential ADME service evaluates reversible drug transfer between compartments, providing insights into pharmacokinetics, bioavailability, and potential interactions.

Our hERG Safety Screening service employs the Synchropatch-384 automated patch clamp system to assess compound effects on the hERG potassium channel. This high-throughput assay detects inhibitors that may prolong QT intervals and cause arrhythmias, aiding early drug safety evaluation. With precise data under physiological conditions, it supports regulatory compliance to advance safer therapeutics. 

Our Metabolite Identification service employs HRMS /LC-MS/MS to decode degradation pathways of antisense oligonucleotides (ASOs), siRNAs, and modified variants, identifying chain-shortened metabolites (5’/3’ cleavage), phosphorothioate changes (desulfurization, inversion) and base/nucleotide alterations (deamination/depurination). Through plasma/tissue/cell analysis, we reveal metabolic stability, biodistribution, and exonucle…

Our Metabolite Identification service for Antibody-Drug Conjugates (ADCs) applies immuno-capture and HRMS to detect payload-containing catabolites, linker cleavages, and biotransformations in biological samples. This targeted assay quantifies free payloads, metabolites, and intact conjugates, assessing stability and off-target risks. Essential for ADC development, it informs payload design and pharmacokinetics, ensuring compli…

Our Cassette and Discrete PK Study service evaluates pharmacokinetic profiles of small molecules in key preclinical species: rat, mouse, dog, and monkey. Using cassette dosing for high-throughput screening of multiple compounds simultaneously and discrete dosing for precise individual assessments for ADME parameters. This aids in early drug optimization, predicting human PK, and ensuring regulatory compliance for safer candida…

The ecTOF is the world’s first GC-HRMS with simultaneous acquisition of EI (Electron Ionization) and CI (Chemical Ionization) information in a single injection. While using EI as the gold-standard GC/MS ionization, the ecTOF in parallel operates a novel CI source. This way it simultaneously provides perfectly aligned accurate mass structural and molecular ion information within a single GC run.

The timsMetabo™ is uniquely designed to deliver unprecedented sensitivity, separation power and annotation confidence for small molecules. Bruker’s technology and workflow innovations combine depth and selectivity for the ultimate in profiling and targeted applications.

Accelerating radiopharmaceutical development in oncology

A compact benchtop design that incorporates 2 or 10 individually powered, high-output stirring stations which can prepare samples for content uniformity testing up to 90% faster than conventional methods.​

Rainbow is an in-situ, fiber optic probe-based, concentration monitor that measures concentration and changes in concentration in real-time without the need for sampling.

Sirius T3 measures pKa, log P, and the solubility of ionizable drugs and small molecules using sub-milligram quantities of samples.

Pion’s PAMPA high-throughput permeability assay uses a range of membranes to mimic physiologic conditions. It allows you to evaluate the passive permeability of API’s as well as the absorption potential of simple or complex formulations using robust models and protocols in a 96-well format.

The SCISSOR is an in-vitro subcutaneous injection site simulator that provides biopharma scientists insights into the behavior of their sub-Q drug candidates.

From small-scale R&D to large-scale manufacturing, Pion homogenizers deliver exceptional fluid processing for particle size reduction (micronization,) cell disruption, and the creation of stable micro- and nanoemulsions and dispersions. Built for scalability, we make the transition from lab to commercial production seamless. Trusted by pharmaceutical, biotech, cannabis, chemical, and food and beverage manufacturers worldwide.

Achieve ultra-high RNA yields with MEGAscript™ kits—ideal for in vitro or in vivo translation studies needing unlabeled or low specific activity RNA.

Discover a world of possibilities with Invitrogen Vivofectamine Delivery Solutions. Rationally designed for in vivo delivery of nucleic acid vaccines and therapeutics, Vivofectamine products and services offer you a distinct edge in basic research and therapeutic development with LNP technology.

Simplify synthesis and scale-up of potent mRNA with third-generation CleanCap®—proven technology for enhanced in vivo translatability.

Hypoxia Workstation